Key clinical point: Disease progression was associated with a worsening of health-related quality of life (HRQOL) among patients with metastatic cancers.
Major finding: Significant deterioration after the first disease progression occurred in 37 of 45 HRQOL scales overall, 17 of which were considered clinically meaningful.
Study details: An analysis of prospectively collected German registry data including 2,314 patients with metastatic colorectal, lung, pancreatic, or breast cancer.
Disclosures: The registries are funded by iOMEDICO and industry sponsors. The authors disclosed relationships with iOMEDICO and several pharmaceutical companies.
Marschner N et al. JAMA Netw Open. 2020 Mar 10. doi: 10.1001/jamanetworkopen.2020.0643.